Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
PJ Mease, BS Goffe, J Metz, A VanderStoep, B Finck… - The Lancet, 2000 - thelancet.com
… Philip J Mease … Additionally, PJ Mease was principal investigator of the study and did
the rheumatology assessments, BS Goffe did the dermatology assessments, and J Metz …
the rheumatology assessments, BS Goffe did the dermatology assessments, and J Metz …
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double‐blind, randomized, placebo‐controlled trial
PJ Mease, DD Gladman, CT Ritchlin… - … : Official Journal of …, 2005 - Wiley Online Library
Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …
evaluated for its safety and efficacy compared with placebo in the treatment of active …
Epidemiology of psoriatic arthritis in the population of the United States
JM Gelfand, DD Gladman, PJ Mease, N Smith… - Journal of the American …, 2005 - Elsevier
BACKGROUND: Estimates of the prevalence of psoriatic arthritis vary widely and are usually
not determined by population-based studies. OBJECTIVES: We sought to determine the …
not determined by population-based studies. OBJECTIVES: We sought to determine the …
Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial
…, EC Keystone, DE Furst, PJ Mease… - Annals of internal …, 1999 - acpjournals.org
Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …
2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria
…, DL Goldenberg, W Häuser, RL Katz, PJ Mease… - Seminars in arthritis and …, 2016 - Elsevier
… Wolfe MD a b , Daniel J. Clauw MD c , Mary-Ann Fitzcharles MD d , Don L. Goldenberg
MD e f , Winfried Häuser MD g h , Robert L. Katz MD i , Philip J. Mease MD j k , Anthony S. …
MD e f , Winfried Häuser MD g h , Robert L. Katz MD i , Philip J. Mease MD j k , Anthony S. …
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
PJ Mease, AJ Kivitz, FX Burch, EL Siegel… - … : Official Journal of …, 2004 - Wiley Online Library
Objective Etanercept has been shown to improve the articular and cutaneous manifestations
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect …
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect …
Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis
LC Coates, A Kavanaugh, PJ Mease… - Arthritis & …, 2016 - Wiley Online Library
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double‐blind, placebo‐controlled trial
LJ Crofford, MC Rowbotham, PJ Mease… - Arthritis & …, 2005 - Wiley Online Library
Objective Fibromyalgia syndrome (FMS) is characterized by widespread musculoskeletal
pain and lowered pain threshold. Other prominent symptoms include disordered sleep and …
pain and lowered pain threshold. Other prominent symptoms include disordered sleep and …
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled …
IB McInnes, PJ Mease, B Kirkham, A Kavanaugh… - The Lancet, 2015 - thelancet.com
Background Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …
[HTML][HTML] Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis
PJ Mease, IB McInnes, B Kirkham… - … England Journal of …, 2015 - Mass Medical Soc
Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …
Related searches
- philip j mease amgen
- philip j mease abbvie
- philip j mease grant
- philip j mease ucb
- philip j mease abbott
- philip j mease speakers bureau
- philip j mease novartis
- philip j mease disclosure of interests
- philip j mease eli lilly
- philip j mease janssen
- philip j mease pfizer
- philip j mease employee
- philip j mease consultant
- philip j mease boehringer ingelheim
- philip j mease bristol-myers squibb
- philip j mease ucb pharma